Prevention of autoimmune diabetes by immunogene therapy using recombinant vaccinia virus expressing glutamic acid decarboxylase
US6991792B2 · kind B2 · utility
0Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2001 |
| Grant date | Jan 31, 2006 |
| Priority date | — |
| Expiry date | May 18, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/023
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A vaccine including recombinant vaccinia virus (ATCC VR-1354) having an inserted gene for coding glutamic acid decarboxylase is used for preventing type 1 diabetes mellitus. The glutamic acid decarboxylase expressed from the recombinant virus suppresses or tolerizes the autoreactive T cell, and induces immunological tolerance, thus effectively prevents or delays the development of type 1 diabetes mellitus.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.